Please use this identifier to cite or link to this item: https://hdl.handle.net/1/2036
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCook, Theresa A-
dc.contributor.authorJayamanne, Dasantha-
dc.contributor.authorWong, Matthew-
dc.contributor.authorCove, Nicola-
dc.contributor.authorBack, Michael-
dc.contributor.otherWheeler, H.-
dc.contributor.otherParkinson, J.-
dc.contributor.otherCook, R. J.-
dc.contributor.otherKastelan, M. A.-
dc.contributor.otherBrown, C.-
dc.date.accessioned2021-10-11T00:44:09Z-
dc.date.available2021-10-11T00:44:09Z-
dc.date.issued2021-06-09-
dc.identifier.citation8(5):601-608en
dc.identifier.issn2054-2577en
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/2036-
dc.description.abstractBACKGROUND: There is minimal evidence to support decision making for symptomatic steroid-refractory pseudoprogression or true progression occurring after intensity-modulated radiation therapy (IMRT) for glioblastoma (GBM). This study audited the survival outcome of patients managed with redo craniotomy (RedoSx) or bevacizumab (BEV) for steroid-refractory mass effect after IMRT for GBM. METHODS: Patients with GBM managed between 2008 and 2019 with the EORTC-NCIC Protocol were entered into a prospective database. Patients with symptomatic steroid-refractory mass effect within 6 months of IMRT managed with either RedoSx or BEV were identified for analysis. For the primary endpoint of median overall survival (OS) postintervention, outcome was analyzed in regards to potential prognostic factors, and differences between groups were assessed by log-rank analyses. RESULTS: Of the 399 patients managed with the EORTC-NCIC Protocol, 78 required an intervention within 6 months of IMRT completion for either true or pseudoprogression (49 with RedoSx and 29 with BEV). Subsequently, 20 of the 43 patients managed with RedoSx when BEV was clinically available, required salvage with BEV within 6 months after RedoSx. Median OS postintervention was 8.7 months (95% CI: 7.84-11.61) for the total group; and 8.7 months (95% CI: 6.8-13.1) for RedoSx and 9.4 months (95% CI: 7.8-13.6) for BEV (P = .38). Subsequent use of BEV in RedoSx patients was not associated with improved survival compared with RedoSx alone (P = .10). Age, time from IMRT, and ECOG performance status were not associated with OS. In the RedoSx patients, immunohistochemical features such as Ki-67% reduction correlated with survival. The presence of pure necrosis and residual tumor cells only had improved survival compared with the presence of gross tumor (P < .001). CONCLUSIONS: At time of symptomatic steroid-refractory true or pseudoprogression following IMRT for GBM, BEV was equivalent to RedoSx in terms of OS. Pseudoprogression with residual cells at RedoSx was not associated with worse outcome compared to pure necrosis.en
dc.description.sponsorshipCentral Coast Cancer Centreen
dc.description.sponsorshipRadiation Oncologyen
dc.subjectCanceren
dc.subjectNeurologyen
dc.subjectRadiologyen
dc.titleRedo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastomaen
dc.typeJournal Articleen
dc.identifier.doi10.1093/nop/npab034en
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34594572/en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesGosford Hospitalen
dc.identifier.journaltitleNeuro-oncology Practiceen
dc.relation.orcidhttp://orcid.org/0000-0002-5363-3974en
dc.relation.orcidhttps://orcid.org/0000-0003-4503-2922en
dc.relation.orcidhttp://orcid.org/0000-0003-2363-8333en
dc.originaltypeTexten
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Oncology / Cancer
Radiology
Show simple item record

Page view(s)

42
checked on Sep 25, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.